preparation and evaluation of a liposome drug delivery system in cancer treatment in vitro

Cancer is a fatal disease and relatively widespread in the world; breast cancer is the most prevalent cancer among women. hydroxyurea (hu) is a chemotherapy drug for the cure of cancer different types in patients, for example breast cancer, but has several defects, for to remove these problems in this study a nanoliposome (nl) suspension for hydroxyurea (hu) delivery in breast cancer cell therapy was developed.hu was encapsulated into nls. size was measured by nanosizer. the release of the liposomal formulation was assessed during 36 h. ftir analysis for liposomal hydroxyurea and free hydroxyurea was carried out. the uptake capacity of the formulation was determined by transfection of nanoliposomal hydroxyurea (nl-hu) in mda-mb231 cells via flow cytometer and fluorescence microscopy studies, the cytotoxicity of nlhu and free hu was evaluated in cells. size of nl-hu was 174nm, hu encapsulation efficiencies in nls was 81%. ftir analysis showed the stability of hu in the liposome and no improper interaction between liposome and hu, release after 36h depicted sustained release behavior. nl-hu had suitable uptake in mda-mb231 cells. cytotoxicity of nlhu on cells was considerable. we confirmed these nanoliposomes are potentially useful for delivery of hydroxyurea in breast cancer cells treatment.